posted on
Jul 07, 2010 03:56AM
Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.
Message: Re: Miles....
Jul 06, 2010 05:29PM
4
Jul 06, 2010 05:32PM
9
Jul 06, 2010 05:55PM
that might actually be attractive to investors if the dividend payout is high enough
Unfortunately, this proposition is speculative as to revenue potential and the effect of an ever decreasing set of licensees, notwithstanding the acknowledged expiry of the respective patents.
For example, if PTSC has cash reserves of $200million, the share price would rise to reflect that cash position. The price would further rise with the announcement of dividends. With each qualifying date for receipt of a dividend, and subsequent payment, the share price would fall, with the cycle repeating itself until all MMP Portfolio income was exhausted. While this might be attractive to traders, I fail to see how this increases shareholder value.
With no further MMP Portfolio revenues, a zero cash balance, and share price languishing who knows where, this would be an outright dereliction of duty by the BoD, which, as you have frequently stated, should be to grow shareholder value, not run it into the ground.
This brings us to M&A which I shall discuss later, as I have a prior appointment to attend.
.
.
.
Be well
9 Recommendations
Loading...
Loading...
2
Jul 08, 2010 11:06AM
9
Jul 08, 2010 11:34AM
5
Jul 08, 2010 02:28PM
9
Jul 08, 2010 04:45PM
7
Jul 08, 2010 04:57PM
7
Jul 08, 2010 05:00PM
9
Jul 08, 2010 05:13PM
2
Jul 08, 2010 05:18PM
New Message
Please
login
to post a reply